Analysis of Scion Asset Management Q3 2025 Portfolio: A Bifurcated Strategy of Macro-Shorts and Idiosyncratic Value

I. Executive Summary: A Portfolio of High-Conviction Extremes#

The Q3 2025 13F filing from Scion Asset Management, managing a portfolio with a reported notional value of $1.38 billion, marks a dramatic strategic pivot. The portfolio is not a diversified collection of equities but rather a highly concentrated, bifurcated structure built on two distinct and nearly opposing theses:

1. A Massive Macro-Short: An approximately $1.1 billion directional bet against the Artificial Intelligence (AI) sector. This is comprised of large put option positions on Palantir ($PLTR) and Nvidia ($NVDA), representing a combined \approx 80% of the portfolio's reported notional value.

2. An Idiosyncratic Long Book: A small, highly selective basket of long positions-in both common stock, preferred stock, and call option form-focused on non-AI, contrarian sectors. These include financials, healthcare, and traditional energy.

This filing reveals a major portfolio reshuffling. Scion exited all option positions held in the previous quarter and liquidated numerous equity stakes. In their place, the fund established these massive new put positions alongside new call options and new equity holdings.

Significantly, this portfolio does not appear to be a hedge. Scion's Q1 2025 filing included a disclosure that its puts "may serve to hedge long positions". The Q3 2025 filing conspicuously contains no such qualifying statement. This absence signals a clear, high-conviction, and directional bearish bet against the AI-driven market.

The table below summarizes the portfolio's top-level structure, highlighting the security type (Put, Call, or Stock) to clarify the true allocation of risk and strategic intent.

Table 1: Scion Asset Management Top Holdings (Q3 2025)

Source: Compiled from Q3 2025 regulatory filings

II. The $1.1 Billion "AI Bubble" Short: A Forensic Thesis#

The dominant feature of Scion's portfolio is its massive bearish wager against AI. The fund opened substantial new put option positions against AI leaders Nvidia ($NVDA) and Palantir ($PLTR). These trades target two of the market's highest-flying stocks, which had seen extreme year-to-date gains of 54% and 174%, respectively, at the time of the filing.

This trade aligns directly with public warnings from Dr. Burry. He posted "sometimes, we see bubbles" on the social media platform X and, more pointedly, shared a graphic from a Bloomberg News story regarding "circular financing" concerns surrounding Nvidia and other AI-related firms.

This public "circular financing" post provides the analytical key to the short thesis. The bet is not merely that $NVDA is "expensive" on a traditional price-to-earnings basis; it appears to be a forensic argument questioning the legitimacy and sustainability of its reported revenues. This "circular" or "reflexive loop" is a classic hallmark of a market top, reminiscent of the "vendor financing" and "telecom capacity swaps" that masked underlying weakness before the 2000-2002 market crash.

The mechanism of this "circular" loop, as detailed in public reports, functions as follows:

1. Nvidia Invests in AI: Nvidia announces a $100 billion investment in OpenAI.

2. AI Buys from Nvidia: OpenAI, a primary recipient of this capital, uses the funds to place massive orders for Nvidia's high-margin chips. This spending is then booked as revenue by Nvidia.

3. Cloud Providers Buy from Nvidia: Concurrently, cloud providers like Oracle spend tens of billions of dollars on Nvidia's chips to build out their AI infrastructure.

4. AI Buys from Cloud Providers: OpenAI (through its partnership with Microsoft Azure) then becomes a major customer of this new cloud infrastructure, effectively "renting" the same chips Oracle just bought.

This loop can artificially inflate revenues, margins, and valuations for all participants, creating a "dangerous bubble" where reported demand is not purely organic but rather a function of interconnected capital flows. Scion's $1.1 billion short position is a direct bet that this entire structure is fragile, unsustainable, and poised for a sharp correction.

III. Defensive & Cyclical Longs: The "Barbell" Call Options#

As a counterbalance to the massive tech short, Scion established new bullish call option positions in Halliburton ($HAL) and Pfizer ($PFE). These positions are not random; they represent the ideological and economic opposite of the AI short, creating a sophisticated "barbell strategy."

• Halliburton ($HAL): A $61.5 million call position on a traditional, cyclical energy services company. This is a leveraged bet on "real assets" and a potential inflationary economic environment.

• Pfizer ($PFE): A $153 million call position on a defensive, "fallen angel" healthcare giant. This is a leveraged bet on a non-cyclical, deep-value cash flow stream.

This portfolio construction forms a "barbell" designed to profit from market dislocation.

• Side 1 (Short): A massive bet on a deflationary event-the "AI bubble" bursting, likely leading to a broad, tech-led market correction.

• Side 2 (Long): Leveraged bets (via calls) on inflationary assets (Energy/HAL) and defensive, deep-value stalwarts (Healthcare/PFE).

Scion is thus positioned to profit if the AI bubble bursts, but also profits if persistent inflation and "old economy" fundamentals re-assert their dominance. This asymmetric structure is designed to capitalize on market extremes, regardless of which direction the market breaks.

IV. Forensic Analysis: Scion's New & Added Equity Positions#

The remainder of this report provides a deep forensic analysis of the four long equity and equity-like positions identified in the Q3 2025 filing: SLM Corporation ($SLM), Molina Healthcare ($MOH), Lululemon Athletica ($LULU), and Bruker Corporation Preferred Stock ($BRKRP).

Each stock will be stress-tested against the 5-category, 20-point "Deep Value / Great Company" framework. However, a crucial analytical exception must be made for the Bruker position.

Analyst Exception: The Bruker ($BRKRP) Special Situation#

Before proceeding to the scorecards, the Bruker position must be analytically separated. Scion's filing shows a liquidation of its entire common stock position in Bruker ($BRKR). In its place, the fund purchased a new $13.1 million position in $BRKRP.

Research identifies $BRKRP as the "6.375% Mandatory Convertible Preferred Stock, Series A". This is not a "deep value" common stock investment; it is a "special situation" play. Scion has intentionally swapped its common equity risk for a fixed-income-like instrument. This preferred stock provides a high, secure 6.375% dividend and has a mandatory conversion feature, binding it to the company's future equity value.

This trade represents a capital structure arbitrage. Scion is de-risking its exposure to $BRKR's common stock volatility while capturing a high, fixed-income-like yield. Therefore, applying traditional value metrics (P/E, P/B, ROE) to this preferred stock is analytically invalid. This position is excluded from the 20-point "Great Company" analysis, as it represents a different asset class entirely.

The following analysis will focus on the three remaining common stock positions: $SLM, $MOH, and $LULU.

V. Deep Value Scorecard: SLM Corporation (NASDAQ: SLM)#

• Company Profile: SLM Corporation, commonly known as Sallie Mae, is a consumer bank that originates, services, and collects private education loans in the United States.

• Chinese Name: 学贷美 (Xué Dài Měi).

• Analyst's Thesis: This position is a classic contrarian, "deep value" play. The stock appears statistically cheap on headline valuation metrics (P/E, PEG). However, as a bank, its business model is built on high leverage, causing it to inherently fail "Balance Sheet Safety" standards designed for industrial or consumer companies. This is a bet on a mispriced asset, not a "Great Company."

Table 2: Deep Value Scorecard: SLM Corporation

• Analyst's Verdict: Does SLM Pass the "Great Company" Standard?

  • Verdict: FAIL.

  • Reasoning: SLM is a quintessential "deep value" stock, but it is not a "great company" by these standards. It passes the valuation tests (P/E, PEG, MoS), suggesting it is cheap. It also shows phenomenal profitability relative to its equity (high ROE, Net Margin). However, it catastrophically fails the Balance-Sheet Safety standards (D/E, Current Ratio) and has a low Return on Assets (ROA). This combination indicates its high returns are a product of extreme financial leverage, not operational excellence. The non-linear EPS record and volatile FCF also make it fail the "Predictability" standard. This is a high-risk, leveraged bet on a financially complex, statistically cheap asset.

VI. Deep Value Scorecard: Molina Healthcare, Inc. (NYSE: MOH)#

• Company Profile: A FORTUNE 500 company that provides managed healthcare services, specializing in government-sponsored programs like Medicaid and Medicare.

• Chinese Name: 莫利纳医疗保健 (Mòlì nà yīliáo bǎojiàn).

• Analyst's Thesis: This investment appears to be a "Great Company at a Reasonable Price" (GARP) play. Molina's stock has faced recent volatility and reported concerns over high medical cost trends. Scion is likely acquiring a high-quality compounder, evidenced by its strong historical returns on capital and solid balance sheet, during a period of temporary, cyclical pessimism.

Table 3: Deep Value Scorecard: Molina Healthcare, Inc.

• Analyst's Verdict: Does MOH Pass the "Great Company" Standard?

  • Verdict: PASS.

  • Reasoning: Molina Healthcare is a high-quality compounder. It passes a majority of the applicable standards. Although it fails the "predictability" metrics due to a major 2017 restructuring and subsequent turnaround , its performance since then has been exceptional. It passes the 10-year BVPS growth standard, generates a high "Owner's Earnings" yield, and demonstrates a safe balance sheet (passing Interest Coverage, Current Ratio, and D/A test). Its profitability is elite, passing the 5-year average standards for ROE (29.4%), ROIC (15.1%), and ROA (6.9%). It fails on P/B, D/E, and Net Margin, but these are largely artifacts of its managed care/insurance industry. Scion is buying a high-ROIC, shareholder-friendly company at a deep value price.

VII. Deep Value Scorecard: Lululemon Athletica Inc. (NASDAQ: LULU)#

• Company Profile: A premier designer, distributor, and retailer of technical athletic apparel, footwear, and accessories, defined by its strong, high-margin brand.

• Chinese Name: 露露柠檬 (Lùlù níngméng).

• Analyst's Thesis: This is a pure GARP (Growth at a Reasonable Price) investment. Scion doubled its equity position in $LULU , signaling high conviction. Lululemon is a "Great Company" by almost every profitability metric (margins, ROE, ROIC) and maintains a fortress balance sheet. The stock's recent price decline has brought its valuation (P/E, PEG) into "value" territory for the first time in years.

Table 4: Deep Value Scorecard: Lululemon Athletica Inc.

| Category | Metric | Value Standard | LULU TTM/Historical Data | Verdict | | :--- | :--- | :--- | :--- | :--- | | 1. Valuation | P/E \leq 15 (vs. history) | \leq 15 | TTM P/E: 11.2 to 11.6. | PASS | | | PEG Ratio < 1 | < 1 | TTM PEG: 0.81. | PASS | | | P/B Ratio \leq 1.5 | \leq 1.5 | TTM P/B: 4.49. | FAIL | | | Margin of Safety \geq 25% | \geq 25\% | Multiple models show high MoS: 46% , 48% , 30%. | PASS | | 2. Cash Generation | FCF: Positive each year | Positive | 10-Yr FCF is volatile. 2023 FCF was low ($328M). Fails "rising" and "stable" test. | FAIL | | | FCF/Revenue > 5% | > 5\% | TTM FCF/Rev: 10.7%. However, 2023 was 4.0% ($328M / 8.1B). Fails "each year" rule. | FAIL | | | Ret. on Ret. Earn. \geq 12% | \geq 12\% | 10-Year Avg ROE is exceptionally high (see below, >30\%), indicating massive compounding of retained earnings. | PASS | | 3. Growth | EPS: Positive & rising 10 yrs | Positive & Rising | 10-Yr EPS : $1.89 (2016), 1.90 (2018), $4.50 (2021), $6.68 (2023)$. Not rising every year (dips in 2018, 2021, 2023). | **FAIL** | | | BVPS 10-yr CAGR $\geq$ 10% | $\geq 10\%$ | BVPS 2016-2025 (9-Year) CAGR = **19.5%**. (Calculated from [span_153](start_span)[span_153](end_span)[span_155](start_span)[span_155](end_span)). | **PASS** | | | Owner's Earnings (OE) / Mkt Cap $\geq$ 10% | $\geq 10\%$ | OE (2025): $1.575B.[span_157](start_span)[span_157](end_span) Mkt Cap: $19.02B. ($1.575 / 19.02$) = **8.3%**. | **FAIL** | | **4. Balance Sheet[span_137](start_span)[span_137](end_span)** | Debt-to-Equity < 0.5 | $< 0.5$ | TTM D/E: **0.40**. | **PASS** | | | Interest Coverage $\geq$ 3$\times$ | $[span_140](start_span)[span_140](end_span)\geq 3\times$ | Interest Expense is **Not Applicable**.[span_158](start_span)[span_158](end_span)[span_159](start_span)[span_159](end_span) Company ended 2024 with "no debt".[span_160](start_span)[span_160](end_span) | **PASS** | | | Interest Exp / Op. Inc $\leq$ 15% | $\leq 15\%$ | **0.0%**. | **PASS** | | | Current Ratio > 1.5 | $> 1.5$ | TTM Current Ratio: **2.27**. | **PASS** | | **5. Profitability** | Gross Margin $\gtrsim$ 40% | [span_141](start_span)[span_141](end_span)$\gtrsim 40\% | 10-Year Avg GM is >50\%. TTM GM: 59.1%. | PASS | | | Net Profit Margin \gtrsim 20% | \gtrsim 20\% | TTM Net Margin: 16.4% to 17.1%. (Elite, but fails the 20% rule). | FAIL | | | ROE \geq 15% (10-yr avg) | \geq 15\% | 10-Year Avg ROE is consistently >30\%. TTM ROE: 40.7%. | PASS | | | ROIC \geq 12% (10-yr avg) | \geq 12\% | 5-Year Avg ROIC: 47.9%. TTM ROIC: \approx 30-33\%. | PASS | | | ROA \geq 6% | \geq 6\% | 10-Year Avg ROA is >20\%. TTM ROA: 23.7%. | PASS | | | Depreciation / Gross Profit \leq 10% | \leq 10\% | TTM D&A: $1.108B. TTM GP: $6.44B. Ratio = 17.2%. | FAIL |

• Analyst's Verdict: Does LULU Pass the "Great Company" Standard?

  • Verdict: PASS.

  • Reasoning: Lululemon is the archetype of a "Great Company." It passes 14 of the 19 applicable standards. Its "Passes" are concentrated in the most critical areas: a fortress Balance Sheet Safety (all four metrics pass, with zero interest expense ) and elite Profitability (GM, ROE, ROIC, and ROA all pass). Its 10-year BVPS growth is exceptional at 19.5%. The position fails primarily on "Predictability" metrics (EPS/FCF not linearly rising, an almost impossible standard) and a few valuation/margin metrics (P/B, Net Margin, OE Yield). Scion doubling its stake confirms this is a high-conviction bet on a wide-moat compounder acquired at a rare moment of valuation discipline (P/E < 15, PEG < 1).

VIII. Final Concluding Thesis: A Portfolio of Extremes#

The Scion Asset Management Q3 2025 portfolio is a masterclass in high-conviction, asymmetric portfolio construction. It is a portfolio of extremes, bifurcated between one giant macro-short and a handful of uncorrelated, idiosyncratic longs.

The short thesis ($1.1 billion in puts on $NVDA and $PLTR) is not a simple valuation call. It is a sophisticated, forensic-accounting-driven bet that the AI revenue boom is artificially inflated by a "circular financing" loop. This thesis mirrors the mechanics of the 2000-2002 dot-com bust and represents a directional bet on a major market dislocation.

The long book acts as a curated "anti-AI" portfolio, diversified by thesis type:

• GARP / "Great Companies": Molina Healthcare ($MOH) and Lululemon ($LULU) both PASS the rigorous "Great Company" framework. They are high-quality, wide-moat compounders (high ROE, high ROIC, safe balance sheets) that were acquired after their stock prices fell to "deep value" valuation levels (P/E < 15, PEG < 1).

• Deep Value / "Cigar Butt": SLM Corp ($SLM) FAILS the "Great Company" framework. It is a high-risk, high-leverage "cigar butt" that is statistically cheap but fails catastrophically on balance-sheet safety metrics.

• Special Situation / Arbitrage: The Bruker ($BRKRP) preferred stock purchase, paired with the sale of the $BRKR common stock, is a pure capital structure arbitrage play, not a traditional value investment.

This 13F filing demonstrates that Scion Asset Management is not operating as a simple, diversified "buy and hold" value fund. It is acting as a macro-timing specialist, using deep forensic analysis to place massive, asymmetric bets on market dislocations (the AI short) while simultaneously bottom-fishing for high-quality, non-correlated compounders ($MOH, $LULU) and high-risk special situations ($SLM).

Works cited#

1. Big Short' Michael Burry is Betting Against NVIDIA and Palantir, https://www.ndtvprofit.com/markets/the-next-big-short-michael-burrys-scion-bets-11-billion-against-palantir-nvidia 2. Scion Asset Management, LLC Portfolio Holdings - Fintel, https://fintel.io/i/scion-asset-management-llc 3. SCION ASSET MANAGEMENT, LLC Top 13F Holdings - WhaleWisdom.com, https://whalewisdom.com/filer/scion-asset-management-llc 4. Michael Burry's Scion Asset Management Bets Against Nvidia and Palantir, https://www.quiverquant.com/news/Michael+Burry%E2%80%99s+Scion+Asset+Management+Bets+Against+Nvidia+and+Palantir 5. Michael Burry Shorts / Scion Asset Management, LLC Options - Stockcircle, https://stockcircle.com/portfolio/michael-burry/options 6. Michael Burry Portfolio (2025 Q3) - Scion Asset Management Holdings 13F - Valuesider, https://valuesider.com/guru/michael-burry-scion-asset-management/portfolio 7. Michael Burry - Portfolio Update - Q1 2025 - BBAE Pro, https://www.bbae.com/blog/michael-burry-portfolio-update-q1-2025/ 8. Michael Burry buys puts on Nvidia, Palantir, https://www.investing.com/news/stock-market-news/michael-burry-buys-puts-on-nvidia-palantir-4330249 9. Burry Discloses Puts On Nvidia And Palantir After Bubble Warning, https://www.thewealthadvisor.com/article/burry-discloses-puts-nvidia-and-palantir-after-bubble-warning 10. Fund Update: New $13.3M $SLM stock position opened by Scion Asset Management, LLC, https://www.quiverquant.com/news/Fund+Update%3A+New+%2413.3M+%24SLM+stock+position+opened+by+Scion+Asset+Management%2C+LLC 11. Fund Update: New $13.1M $BRKRP stock position opened by Scion Asset Management, LLC - Quiver Quantitative, https://www.quiverquant.com/news/Fund+Update%3A+New+%2413.1M+%24BRKRP+stock+position+opened+by+Scion+Asset+Management%2C+LLC 12. OpenAI, Nvidia fuel $1T AI market with web of circular deals, https://news.ycombinator.com/item?id=45521629 13. Do OpenAI's multibillion-dollar deals mean exuberance has got out of hand? - The Guardian, https://www.theguardian.com/business/2025/oct/08/openai-multibillion-dollar-deals-exuberance-circular-nvidia-amd 14. Circular Financing in AI, Nvidia Funds OpenAI to Buy Its Own Chips - Medium, https://medium.com/@finomicsedge/circular-financing-in-ai-nvidia-funds-openai-to-buy-its-own-chips-72384b2bd66f 15. Nvidia becomes world's first $5tn company amid stock market and AI boom, https://www.theguardian.com/technology/2025/oct/29/nvidia-first-company-5-trillion 16. Circular Investing in the AI Ecosystem - Highline Wealth Partners, https://www.highlinewp.com/post/circular-investing-in-the-ai-ecosystem 17. $48M Michael Burry Portfolio / Scion Asset Management, LLC Holdings - Stockcircle, https://stockcircle.com/portfolio/michael-burry 18. Bruker Announces Public Offering of $600 Million of Mandatory Convertible Preferred Stock, https://ir.bruker.com/press-releases/press-release-details/2025/Bruker-Announces-Public-Offering-of-600-Million-of-Mandatory-Convertible-Preferred-Stock/default.aspx 19. Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock, https://ir.bruker.com/press-releases/press-release-details/2025/Bruker-Announces-Pricing-of-Public-Offering-of-600-Million-of-6-375-Mandatory-Convertible-Preferred-Stock/default.aspx 20. Bruker launches $600 million convertible preferred stock offering - Investing.com, https://www.investing.com/news/company-news/bruker-launches-600-million-convertible-preferred-stock-offering-93CH-4220103 21. SLM Corporation (SLM) Stock Price, Quote, News & Analysis - Seeking Alpha, https://seekingalpha.com/symbol/SLM 22. SLM Corporation - AnnualReports.com, https://www.annualreports.com/Company/slm-corporation 23. Sallie Mae - Wikipedia, https://en.wikipedia.org/wiki/Sallie_Mae 24. 学贷美(SLM) 股价、新闻、报价和图表 - 富途牛牛, https://www.futunn.com/stock/SLM-US 25. 学贷美(SLM) 公司做什么 - 富途牛牛, https://www.futunn.com/stock/SLM-US/company 26. SLM (SLM) Intrinsic Value: Projected FCF - GuruFocus, https://www.gurufocus.com/term/intrinsic-value-projected-fcf/SLM 27. SLM EPS - Earnings per Share 2011-2025 - Macrotrends, https://macrotrends.net/stocks/charts/SLM/slm/eps-earnings-per-share-diluted 28. Investor Relations | Molina Healthcare Inc., https://investors.molinahealthcare.com/ 29. ANNUAL REPORT 2021 - Molina Healthcare Investor Relations, https://investors.molinahealthcare.com/static-files/831b027e-d707-4631-a0a3-1904056cb9e9 30. Molina Healthcare公司简介及介绍 - 富途牛牛, https://www.futunn.com/stock/MOH-US/company 31. 医疗保健管理 - Molina Healthcare, https://www.molinahealthcare.com/members/ca/zh-us/mem/medicaid/medical/coverd/hm/cm.aspx 32. 会员权利与责任 - Molina Healthcare, https://www.molinahealthcare.com/members/ca/zh-us/mem/medicaid/medical/quality/rights.aspx 33. Molina Healthcare (MOH): Assessing Value After Recent Volatility and Share Price Slide, https://simplywall.st/stocks/us/healthcare/nyse-moh/molina-healthcare/news/molina-healthcare-moh-assessing-value-after-recent-volatilit 34. Why Molina Healthcare, Inc.'s (MOH) Stock Is Down 5.01% | AAII, https://www.aaii.com/investingideas/article/317615-why-molina-healthcare-inc8217s-moh-stock-is-down-501 35. Assessing Molina Healthcare After Share Price Falls Over 40% in 2025 - Simply Wall St, https://simplywall.st/stocks/us/healthcare/nyse-moh/molina-healthcare/news/assessing-molina-healthcare-after-share-price-falls-over-40 36. Molina Healthcare Reports Third Quarter 2025 Financial Results, https://investors.molinahealthcare.com/news-releases/news-release-details/molina-healthcare-reports-third-quarter-2025-financial-results 37. Molina Healthcare EPS - Earnings per Share 2011-2025 | MOH - Macrotrends, https://www.macrotrends.net/stocks/charts/MOH/molina-healthcare/eps-earnings-per-share-diluted 38. Molina Healthcare (MOH) Financial Ratios and Metrics, https://stockanalysis.com/stocks/moh/financials/ratios/ 39. lululemon 2024 Annual Report, https://corporate.lululemon.com/~/media/Files/L/Lululemon/investors/annual-reports/lululemon-2024-annual-report.pdf 40. Lululemon 2023 Annual Report, https://corporate.lululemon.com/~/media/Files/L/Lululemon/investors/annual-reports/lululemon-2023-annual-report.pdf 41. 露露柠檬- 维基百科，自由的百科全书, https://zh.wikipedia.org/zh-cn/%E9%9C%B2%E9%9C%B2%E6%9F%A0%E6%AA%AC 42. 不找明星、不聯名露露檸檬打造「邪教般的品牌」，靠這2000人 - 天下雜誌, https://www.cw.com.tw/article/5128702 43. Lululemon Athletica (LULU): Slowing Growth, But a 41% ROE Powerhouse, https://acquirersmultiple.com/2025/09/lululemon-athletica-lulu-slowing-growth-but-a-41-roe-powerhouse/ 44. lululemon athletica inc. (LULU) Statistics & Valuation - Stock Analysis, https://stockanalysis.com/stocks/lulu/statistics/ 45. Lululemon Athletica Inc PE Ratio 2012-2025 | LULU - Macrotrends, https://www.macrotrends.net/stocks/charts/LULU/lululemon-athletica-inc/pe-ratio 46. PEG Ratio For Lululemon Athletica Inc (LULU) - Finbox, https://finbox.com/NASDAQGS:LULU/explorer/peg_ltm/ 47. LULU Intrinsic Valuation and Fundamental Analysis - Lululemon Athletica Inc, https://www.alphaspread.com/security/nasdaq/lulu/summary 48. LULU (Lululemon Athletica) Intrinsic Value: DCF (FCF Based) - GuruFocus, https://www.gurufocus.com/term/intrinsic-value-dcf-fcf-based/LULU 49. Lululemon Athletica Inc Financial Ratios for Analysis 2011-2025 | LULU | MacroTrends, https://www.macrotrends.net/stocks/charts/LULU/lululemon-athletica-inc/financial-ratios 50. Lululemon Athletica Inc Free Cash Flow 2012-2025 | LULU - Macrotrends, https://www.macrotrends.net/stocks/charts/LULU/lululemon-athletica-inc/free-cash-flow 51. Lululemon Athletica Inc Revenue 2012-2025 | LULU - Macrotrends, https://www.macrotrends.net/stocks/charts/LULU/lululemon-athletica-inc/revenue 52. Lululemon Athletica Inc EPS - Earnings per Share 2012-2025 | LULU | MacroTrends, https://www.macrotrends.net/stocks/charts/LULU/lululemon-athletica-inc/eps-earnings-per-share-diluted 53. Key Metrics - Lululemon Athletica Inc LULU - Morningstar, https://www.morningstar.com/stocks/xmex/lulu/key-metrics 54. LULULEMON ATHLETICA INC (LULU) Stock Fundamental Analysis - Chartmill, https://www.chartmill.com/stock/quote/LULU/fundamental-analysis 55. Lululemon (LULU) Research Report - StockStory, https://stockstory.org/us/stocks/nasdaq/lulu 56. Lululemon Athletica Inc. (LULU) Return on Invested Capital (ROIC) annual & quarterly (2006-2025) - Value Sense, https://valuesense.io/ticker/lulu/roic 57. Lululemon Athletica Inc Total Depreciation and Amortization - Cash Flow 2012-2025 | LULU, https://www.macrotrends.net/stocks/charts/LULU/lululemon-athletica-inc/total-depreciation-amortization-cash-flow 58. lululemon athletica (LULU) - Shares outstanding - Companies Market Cap, https://companiesmarketcap.com/lululemon-athletica/shares-outstanding/